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Summary 
Autoantibodies occur in low frequencies among patients with myositis characterizing only dis- 
tinct subsets of this disease. Most of these known antibodies are directed to enzymatically active 
complexes. The 20S proteasome represents an essential  cytoplasmatic protein complex for in- 
tracellular nonlysosomal protein degradation, and is involved in major histocompatibility com- 
plex class I restricted antigen processing. In this study we investigated whether the 20S protea- 
some complex is an antibody target in myositis and in other autoimmune diseases.  34 sera  of 
poly/derrnatomyositis  patients  were  assayed  for  antiproteasomal  antibodies  using  enzyme- 
linked immunosorbent assay, immunoblot, and two-dimensional non-equilibrium pH gradient 
electrophoresis (NEPHGE). Sera was from patients with systemic lupus erythematosus (SLE), 
mixed connective tissue disease, and rheumatoid arthritis; healthy volunteers served as controls. 
In 62% (21/34) of the cases sera from patients with myositis and in 58% (30/52) of the cases 
sera  from patients with  SLE reacted with  the  20S  proteasome.  These frequencies exceeded 
those  of sera  from patients  with  mixed  connective tissue  disease,  rheumatoid  arthritis,  and 
healthy controls. The c~-type subunit C9 of the 20S proteasome was determined to be the pre- 
dominant target of the autoimmune sera in myositis and SLE. Lacking other frequent autoanti- 
bodies in myositis, the antiproteasome antibodies are the most common humoral immune re- 
sponse so far detected in this disease entity. 
W 
ithin eukaryotic cells the 20S proteasome (multicat- 
alytic  proteinase  complex)  represents  the  key  en- 
zyme  complex  responsible  for  intracellular  nonlysosomal 
protein degradation, and is the proteolytic core of an even 
larger 26S protease complex which is involved in the ATP/ 
ubiquitin-dependent protein degradation (1).  Proteasomes 
are involved in the degradation or processing of transcrip- 
tions factors such as nuclear factor (NF)KB, in cyclin degra- 
dation,  cell  cycle  control,  and  apoptosis  (1-4).  Further- 
more, the synthesis of the ~3-type subunits LMP2, LMP7, 
and MECL1,  as well as the PA28 regulator, are inducible 
by IFN-% and the role of the 20S proteasome in the pro- 
cessing of antigens presented by MHC class I molecules is 
now well established. Analysis  of the structure and subunit 
sequences revealed that the proteasome is highly conserved 
among species as far apart in evolution as bacteria and man 
(5-8).  In  eukaryotes  the  cylindrical  structure  of protea- 
somes is arranged in four staggered tings composed of 28 
subunits  whereby each  ring  contains seven different pro- 
teins.  The or  subunits  are  located in  the  outer rings 
and are the contact sites for regulatory complexes such as 
the  11S  regulator PA28  and the  19S  complexes.  Four of 
the or-type subunits carry putative nuclear location signals 
and several are substrates for protein kinases (9). The ~3-type 
subunits  forming  the  two  adjacent  inner  rings  carry the 
proteolytically active  sites.  As  deduced  from  the  crystal 
structure of the thermoplasma proteasome and mutagenesis 
only three  out  of the  seven mammalian  [3-type subunits 
within  one ring form active sites  with  the  NH2-terminal 
threonine being the catalytically active residue (10,  11). 
Autoantibodies  play  an  important  diagnostic  role  in 
many autoimmune  diseases.  Thus,  anti-tRNA  synthetase 
autoantibodies  occurring in  myositis  patients  characterize 
clinically different patient subsets  (12).  The cytoplasmatic 
aminoacyl-tRNA synthetases catalyze the binding of amino 
acids  to their cognate tRNA,  and five of them have been 
determined  to  be  the  antigens  of specific  autoantibody 
subtypes (13).  Nevertheless, among myositis patients these 
specific antibodies  are present at  relatively low frequency 
(5-20~  (13). 
The  objective  of the  present  study  was  to  determine 
whether  specific  subunits  of  the  abundant  proteasome 
complex represent disease-specific autoantigens. Therefore, 
sera  of different  types  of chronic  inflammatory  autoim- 
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SLE,  mixed  connective  tissue  disease  [MCTD]),  rheuma- 
toid arthritis (RA), and sera from healthy controls were tested 
in  ELISA,  immunoblot,  and  two-dimensional  NEPHGE. 
The experiments  show for the first time that  sera from pa- 
tients with PM and DM  as well as SLE patients  contain an- 
tiproteasome  antibodies  at  high  frequencies.  Furthermore, 
we  demonstrate  that  the  proteasomal  R-type  subunit  C9 
represents a major immune  target of reactive sera. 
Materials  and Methods 
Patient Sera.  Sera  of the  following individuals  were  investi- 
gated: 8 patients with DM and 26 patients with PM classified ac- 
cording to Bohan and Peter (14,  15),  52 patients with SLE fulfill- 
ing the 1982 revised ACR. criteria 06),  10 patients with MCTD 
diagnosed  according  to  Sharp  et  al.  (17),  20  patients  with  tkA 
(18),  and  112  healthy  controls.  Materials  were  obtained  at  the 
university hospital of the Charit8 Berlin. 
Pur!ficatio~t of20S  Proteasome.  20S  proteasomes  were  isolated 
from  human  erythrocytes  following  standard  procedures,  and 
analysis ofproteasome subunits by two-dimensional electrophoresis 
(NEPHGE/SDS-PAGE) was carried out as described (19,  20). 
Monoclonal Antl~vroteasorne Antibodies.  Mice  were  injected  in- 
traperitoneally with ~25  to  100  Fig proteasome protein in about 
100-200  ~zl  PBS as a water in oil mixture in the same amount  of 
CFA. Booster injections were given after a resting period of 2-3 
too.  Antibody  activity was  determined  in  the  serum  of immu- 
nized mice in general 7  d  after immunization.  Spleen cells were 
taken  4  d  after  the  last  booster  injection  and  fused  with  X63 
Ag8.653  nweloma  cells using polyethylene glycol. A  small por- 
tion of the spleen cells was taken into culture for 7-10 d and anti- 
body activity was measured in solid-phase binding assays after ad- 
sorbing the first reactant to polyvinyl chloride plates according to 
our general methods  (21,22).  The incubation sequences were as 
follows: proteasome, antibody-containing solution, biotin-labeled 
sheep  anti-mouse  Is,  streptavidin-galactosidase  complex.  The 
fluorescence of the substrate 4-methylumbelliferyl galactoside was 
measured at 355 nm. 
lmmunoblotting.  For immunoblotting,  purified proteins  were 
separated by 15% SDS-PAGE and were transferred onto nitrocel- 
lulose membranes.  The remaining binding sites  were blocked for 
2  h  with PBS,  pH 7.4,  containing 5% skim milk.  Subsequently, 
the  patient's  sera  diluted  l:100  were  added.  The  antibodies 
bound  to  the  proteasome  were  detected  by  rabbit  anti-human 
IgG  antibodies  coupled  with  horseradish  peroxidase  diluted  1: 
10,000  in PBS/1% Tween 20/1%  skim milk. Antibodies bound 
were visualized using x-ray films exposed to enhanced chemilu- 
minescence-treated blots  (Boehringer Mannheim  GmbH,  Man- 
nheim, Germany). 
ELISA.  Multititer plates were coated overnight with l  btg/ml 
of the purified proteasome in carbonate buffer, pH 9.6.  Remain- 
ing binding sites  were blocked with 0.5%  skim milk and  0.05% 
Tween 20  in PBS,  pH 7.4.  Human  sera  were diluted  1:100  and 
applied  to  each  well for 2  h  at  room  temperature.  Anti-human 
IgG peroxidase-labeled antibody (I ms/liter) was used as the sec- 
ond reagent.  Bound antibodies were detected enzymatically with 
*  AbbreHatiotls  used i~1  this paper: DM,  dermatomyositis;  MCTD,  mixed 
connective tissue disease; NEPHGE, non-equilibrium pH gradient  dec- 
trophoresis; PM, polymyositis; RA, rhemnatoid  arthritis. 
0-phenylenediamine as substrate  using a microplate reader at 492 
nm. Standard curves were established using the polyclonal protea- 
some-specific antibody MP-3 and mouse anti-rabbit IgG peroxi- 
dase as secondary reagent. MP-3 was diluted in linear steps  start- 
ing  with  1:400.  OD  units  of the  dilution  step  1:12,800  were 
considered to represent a value of 10,000  arbitrary units.  There- 
fore, it was possible to make a direct correlation between the an- 
tibody reactivity of patients  sera  of several assays. 112  sera  from 
normal  controls served to  establish  background  reactivities. The 
mean value plus threefold SD were used as cutoff 
Monoclonal  antiproteasome  antibodies  were  used  to  support 
antiproteasome  antibody  specificity  of  patient  sera.  Multititer 
plates  were  coated  with  the  antiproteasome  antibody  B65-BA5 
diluted  1:1,000 in carbonate buffer, pH 9.6.  Purified proteasome 
was applied at a concentration of 10 ~tg/ml. Human sera were di- 
luted 1:100 and applied to each well for 2 h at room temperature. 
Further,  goat  anti-human  IgG  (Fc  specific)  peroxidase-labeled 
antibody  (affinity-isolated  antibodies,  no  cross-reactivity  with 
mouse  or rat  IgG;  Sigma  Chemical  Co.,  St.  Louis,  MO)  were 
added 1:10,000.  The antibodies bound were detected using 2-acino- 
bis-ethylbenzthiazolin-6-sulfate diammonium as substrate  and mea- 
sured at 405 nm. 
Statistical  Analysis.  Statistics  were  performed  using  the  non- 
parametric  U  test  (Mann  and Whitney)  and  chi-square test with 
Yates correction to compare the qualitative and quantitative reac- 
tivities  to  the  proteasome  among  the  patient's  groups  investi- 
gated. P values of <0.05 were considered to be statistically signif- 
icant. 
Results and Discussion 
Antiproteasome antibodies were detected by ELISA in 21 
of 34 sera  (62%)  derived from PM  (16/26)  and  DM  (5/8) 
patients.  Sera from patients  with  SLE reacted with protea- 
somes in 30 of 52 cases (58%)  using ELISA. These frequen- 
cies of antiproteasome  antibodies  were  significantly higher 
than  those found in patients  with RA  (P <0.001),  MCTD 
(P <0.025),  or in  healthy  controls  (P <0.001)  (Fig.  1).  In 
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Figure  1,  Autoinmmne response against proteasome  was  detected  in 
patients with PM, DM, MCTD, and SLE. ELISA reactivities and median 
values of patients  and healthy  controls  sera to purified  20S proteasome. 
Note that the two antiproteasome-positive  sera of" healthy controls were 
not confirmed  in further specific assays, The respective cut-offvalues are 
indicated  (  ....  ). The strongest autoinmmne response was detected  in 
sera of patients with PM, DM, and SEE. 
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Figure  2.  Antiproteasome antibodies were  confirmed in  a  stringent 
sandwich  ELISA. Multititer  plates were  coated  with  the  monoclonal 
mouse anti-human  proteasome antibody B65-BA5, which served as the 
proteasome-specific reagent. Reactivities and median values of the main 
patient groups are shown. The respective  cutoffvalues  are indicated (- - - -). 
All sera of the healthy controls group were negative. The same sera of pa- 
tients with PM, DM, and SLE revealed positive reaction in both ELISA 
assays. 
fact, sera of patients with PM/DM  and SLE revealed a much 
stronger reactivity with  20S  proteasome protein  than  sera 
from patients with RA (P <0.0005)  and MCTD  (P <0.025). 
Sera of healthy controls gave a  positive reaction in  only 2 
of 112 cases (1.78%). 
To  exclude  the  possibility that  the  above  results  were 
due to nonspecific binding of antibodies and to unequivo- 
cally establish  the  antiproteasome  specificity of the  auto- 
antibodies  of PM/DM  and  SLE  patients,  we  performed 
sandwich ELISAs using the proteasome-specific mAb B65- 
BA5.  In support of the data shown  in Fig.  1,  21  of the 34 
sera tested from both PM  and DM  patients and 30  of the 
52  sera from SLE were also positive in the  more  stringent 
sandwich  ELISA  (Fig.  2).  Furthermore,  the  two  positive 
MCTD  sera were  confirmed in that test.  Importantly, the 
same patient sera were positive in both ELISA systems.  In 
contrast,  the  two  initially reactive sera from  healthy con- 
trois as well as the one reactive RA serum were completely 
negative in the sandwich assay. 
There  was  no  evidence  for  a  statistical correlation  be- 
tween the presence of antiproteasome antibodies and other 
routinely characterized antibody specificities. An exclusive 
presence of antiproteasome antibodies was only observed in 
sera from DM  and PM patients. This contrasts with serum 
samples of SLE, MCTD,  and RA patients, which predom- 
inantly  reacted  with  other  defined  autoantigens  such  as 
anti-native DNA  antibodies (ds-DNA),  anti-small nuclear 
ribonucleoprotein Smith  (Sm),  anti-Ul-ribonucleoprotein 
(U1-R.NP),  or contained rheumatoid factor.  Interestingly, 
of the five sera which were positive for anti-histidyl tP,  NA 
synthetase (Jo-1) antibodies only one serum from the myo- 
sitis group contained antiproteasome antibodies (Table 1). 
To  see  whether  the  antiproteasome  autoantibodies  ob- 
tained from patients with PM/DM  and SLE react with sev- 
eral or a specific type ofproteasome subunits, the respective 
patient  sera  were  probed  on  purified  human  erythrocyte 
20S  proteasome  in  immunoblot  experiments.  Of the  21 
ELISA-positive myositis sera a total of 16  (PM  13/16;  DM 
3/5)  were also positive in immunoblots. All five immuno- 
blot negative sera were  of tow antiproteasome titer as de- 
termined by ELISA. 14 of the  16 antiproteasome autoanti- 
bodies  of PM/DM  patients  tested  exclusively identified a 
single proteasomal subunit of 28 kD and thus revealed a re- 
markable  subunit  specificity (Fig.  3).  The  remaining  two 
sera,  besides exhibiting specificity for  the  28-kD  protein, 
also revealed weak reactivity with a proteasome subunit of 
23  kD.  SLE patients recognized a  single proteasomal sub- 
unit  of 28  kD  in  19  cases.  Only three sera identified sub- 
units  of 28  and  of 23  kD  simultaneously.  Both  positive 
MCTD  sera  recognized  subunits  of 28  kD,  whereas  the 
negative sera revealed no reactivity. It is important to note 
here  that  all ELISA-negative sera,  including the  sera from 
patients  with  PM/DM  and  SLE,  were  also  proteasome 
negative in immunoblots (data not shown). 
Table 1.  Distinct Autoantibody  Profiles of the Different Disease Entities 
ANA  dsDNA  R.F 
IF  IF  APA*  Jo-l*  Scl-70"  Sm*  U1-R.NP*  ELISA 
PM/DM  (n =  34)  26  0  21  5  2  0  0  5 
SLE  (n =  52)  50  45  30  0  0  8  12  12 
MCTD  (n =  8)  8  0  2  0  1  0  8  2 
I<A  (n =  20)  4  0  1  0  0  0  0  19 
Antinuclear antibodies (ANA) detected by indirect immunofluorescence in human larynx epithelioma cancer cell line (Hep-2 cells). The dilutuion 
sera was started at 1:80. Anti-native DNA antibodies (dsDNA)  detected in specific Crithidia luciliae immunofluorescence  test; dilution  of sera was 
started at 1:2. Antiproteasome antibodies (APA),  antihistidyl tl<NA synthetase (Iol), anti-DNA topoisomerase I (Scl-70), anti-small nuclear ribonu- 
cleoprotein  Smith (Sm), and anti-Ul-ribonucleoprotein (UI-RNP) specificities detected in ELISA and immunoblotting assays (dilution of the pa- 
tients sera 1:100). Rheumatoid factors (RF) of the IgM type measured using ELISA. Statistical analysis  indicate that APA is a candidate as a new use- 
ful diagnostic marker ofautoimmune myositis. IF, immunofluorescence; IB, immunoblotting. 
*Antigens identified by immunoblotting and ELISA. 
1315  Feist et al. Figure 3.  Patient sera detect a single proteasorual subunit in Western 
blot analysis. 208  proteasorues were  isolated from  human erythrocytes. 
Representative  sera react with a 28-kD subunit of the proteasorue.  (A) 
Lane  1, 5 l,  tg of purified proteasome,  Cooruassie stained; lane 2, rabbit 
antiproteasome antibody MP-3 as a polyclonal Ab recognized several pro- 
teasomal subunits; lanes 3 and 4, sera of patients with PM; lane 5, serum 
of a patient with DM; lanes 6 and 7, sera of patients with SLE; lane 8, 
healthy control. All positive patients sera recognized a single subunit of 28 
kD. (B) Lane 1, rabbit antiproteasorue antibody MP3; lane 2, serum of a 
patient with PM; lanes 3 and 4, sera of patients with SLE; lane 5, healthy 
control. 
The observation that the autoantibodies reacted predom- 
inantly with  a  single proteasome  subunit after  SDS-PAGE 
led us to determine the identity of the subunit after separa- 
tion  of proteasome  subunits by  two-dimensional electro- 
phoresis  (Fig.  4).  The  high  titer  antiproteasome  sera  of 
PM/DM  and SLE patients used in these experiments iden- 
tified a  single protein which,  as judged by its size,  electro- 
phoretic mobility, and amino acid sequence, represents the 
proteasome o~-type subunit C9  (Fig. 4). 
In this communication we have presented evidence that 
62%  of the  sera  from  patients  with  PM/DM  and  58%  of 
SLE  sera contain autoantibodies which react  with the  208 
proteasome  representing one of the  most abundant intrac- 
ellular proteins.  Furthermore,  we  have  demonstrated  that 
Figure 4.  Subunit C9 is the ruajor target of patients autoantibodies in 
two-dimensional  electrophoresis of 208 proteasorue. Analyses were per- 
fornled  with  proteasorue  of  human  erythrocytes  (first dimension, 
NEPHGE; second dimension, SDS-PAGE). Arrow indicates (x-type sub- 
unit C9. (A) Coomassie staining of a two-dimensional gel shows the puri- 
fied human proteasome.  (B)  Western  blot analysis of two-dimensional 
electrophoresis detected  by one representative serum  of a patient  with 
polyruyositis. Rabbit anti-hurnan IgG antibodies coupled with peroxidase 
served as the secondary reagents. Proteasorual co-type subunit C9 was rec- 
ognized by the patient serum. 
the proteasomal el-type subunit C9 represents the predom- 
inant target of the autoantibodies occurring in myositis pa- 
tients.  Skeletal muscle  cells have  been shown  to  represent 
APC  by processing and presenting antigens to  T  cells via 
MHC  class  I  and  II  pathways  (23).  In  addition,  skeletal 
muscle  cells  themselves  can be  targets  of autoimmune at- 
tack  in inflammatory muscle  diseases  such  as  polymyositis 
and dermatomyositis. Curiously, subunits of the proteolytic 
enzyme  complex  responsible  for  the  processing  of MHC 
class  I  antigens  are  themselves  targets  of  autoantibodies. 
Previously reported myositis-specific autoantibodies recog- 
nize  proteins  of RNP  complexes  involved in  RNA  pro- 
cessing,  protein  translation,  or  protein  translocation  (24). 
The  association  of anti-tRNA  synthetase  antibodies with 
myositis, arthritis, and interstitial lung disease led to the de- 
scription of an entity designated as antisynthetase syndrome 
or  anti-Jo-1  syndrome  and  represents  the  most  common 
disease ofmyositis subgroups (13). 
Nevertheless,  80-85% ofmyositis patients do not possess 
autoantibodies to the previously reported antigens (24, 25). 
Interestingly,  only  5  of  34  sera  from  PM/DM  patients 
tested were anti-Jo-1 positive and of these only one also re- 
vealed  reactivity with  208  proteasome.  This  demonstrates 
that  there  is an infrequent overlap  in the induction of au- 
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This indicates a discrimination between both groups of pa- 
tients and supports the role of antiproteasome C9 autoanti- 
body as a serological marker ofa myositis subset. 
It is  of special clinical interest  that the presence  of anti- 
proteasome antibodies was observed in active inflammatory 
muscle  diseases  in  the  PM/DM  patients  group.  We  ob- 
served  that  the  antiproteasome-positive  cases  of PM/DM 
revealed  no  manifestation  of interstitial  lung  disease.  Fur- 
thermore,  we found that in these positive myositis patients 
a high frequency of other organ involvement due to vascu- 
litis  was  seen.  Remarkably,  besides  an  active  myositis  the 
two antibody-positive MCTD  patients  revealed severe or- 
gan  involvement.  It  is  notable  that  all  patients  with  SLE 
possessing antiproteasome  antibodies  also had severe organ 
manifestations  like  active  nephritis  and  vasculitis  of the 
skin.  Since these patients  did not show any signs of myosi- 
tis,  it may be concluded that the antiproteasome antibodies 
not  only do  not  indicate  muscle  involvement  in  autoim- 
mune  diseases,  but  may also  signify severe  internal  organ 
damage. 
In a  previous  study Arribas  et al.  (26)  reported  an  anti- 
proteasome reactivity in 35% of SLE sera as judged by im- 
munoblotting,  but were not able to detect antiproteasome 
antibodies  in sera of PM/DM  patients.  In that study it re- 
mained  unclear,  however,  which  of the  proteasome  sub- 
units  were  recognized  and  whether  they  all  were  indeed 
subunits of the enzyme complex. 
Here  we  demonstrate  that  antiproteasome  antibodies 
represent one parameter for humoral autoimmune response 
in myositis. In addition to clinical and serological signs, like 
elevated  levels  of creatinine  kinase,  antiproteasome  anti- 
bodies are a candidate for a useful diagnostic marker.  Initial 
data indicate a correlation with disease severity. Thus, clin- 
ical  signs  of an  active  myositis  and  severe  organ  involve- 
ment  appear  to  be  related  to  the  presence  of antiprotea- 
some  antibodies.  However,  the  pathogenic  importance  of 
the antiproteasome antibodies and of the best-described au- 
toantibodies  in  systemic  rheumatic  diseases  remains  un- 
proven  (27).  One  interesting  aspect  of ongoing studies  in 
our laboratories  is  the  modulation  of the  proteinase  func- 
tion by antiproteasome antibodies.  Therefore, epitopes that 
represent  functional  domains  of the  C9  subunit  could  be 
antibody target sites.  The C9 subunit possesses a nuclear lo- 
cation signal and is a component of the outer oL-ring of the 
proteasome which interacts with a number of regulators of 
proteasome activity. One of these is the 11S activator PA28 
which  together  with  the  20S  proteasome  is  directly  in- 
volved in  the MHC  class  I  response  of the  cell.  In recent 
reports it was shown that a large number of autoantibodies 
are also present within the cell (28).  If this turns out also to 
be true for the  C9 autoantibody,  a direct influence  on the 
proteolytic function ofproteasomes appears possible.  Nev- 
ertheless,  more detailed  studies  will be  necessary to  deter- 
mine the relevance of an immune response to proteasomes 
with the predominant recognition of the C9 subunit in pa- 
tients with autoimmune diseases. 
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